全文获取类型
收费全文 | 12058篇 |
免费 | 700篇 |
国内免费 | 194篇 |
专业分类
耳鼻咽喉 | 46篇 |
儿科学 | 264篇 |
妇产科学 | 177篇 |
基础医学 | 2227篇 |
口腔科学 | 508篇 |
临床医学 | 739篇 |
内科学 | 2174篇 |
皮肤病学 | 132篇 |
神经病学 | 1109篇 |
特种医学 | 122篇 |
外国民族医学 | 4篇 |
外科学 | 1073篇 |
综合类 | 532篇 |
现状与发展 | 4篇 |
预防医学 | 407篇 |
眼科学 | 106篇 |
药学 | 2014篇 |
中国医学 | 276篇 |
肿瘤学 | 1038篇 |
出版年
2023年 | 117篇 |
2022年 | 155篇 |
2021年 | 324篇 |
2020年 | 283篇 |
2019年 | 376篇 |
2018年 | 350篇 |
2017年 | 303篇 |
2016年 | 283篇 |
2015年 | 344篇 |
2014年 | 639篇 |
2013年 | 981篇 |
2012年 | 477篇 |
2011年 | 579篇 |
2010年 | 432篇 |
2009年 | 470篇 |
2008年 | 538篇 |
2007年 | 503篇 |
2006年 | 506篇 |
2005年 | 427篇 |
2004年 | 390篇 |
2003年 | 379篇 |
2002年 | 317篇 |
2001年 | 299篇 |
2000年 | 283篇 |
1999年 | 302篇 |
1998年 | 285篇 |
1997年 | 218篇 |
1996年 | 248篇 |
1995年 | 226篇 |
1994年 | 222篇 |
1993年 | 172篇 |
1992年 | 164篇 |
1991年 | 129篇 |
1990年 | 118篇 |
1989年 | 106篇 |
1988年 | 108篇 |
1987年 | 72篇 |
1986年 | 97篇 |
1985年 | 111篇 |
1984年 | 113篇 |
1983年 | 82篇 |
1982年 | 69篇 |
1981年 | 71篇 |
1980年 | 59篇 |
1979年 | 36篇 |
1978年 | 33篇 |
1977年 | 28篇 |
1976年 | 24篇 |
1974年 | 27篇 |
1973年 | 26篇 |
排序方式: 共有10000条查询结果,搜索用时 34 毫秒
11.
12.
13.
目的探讨益气化瘀解毒方干预后对Sorafenib获得性耐药人肝癌QGY7702细胞(QGY7702/Sora)增殖及MRP、GST-π和Topo Ⅱ基因表达的影响。方法培养QGY7702/Sora细胞和QGY7702细胞,利用Cell Counting Kit-8(CCK-8)法检测Sorafenib对细胞的半数抑制率浓度(IC50值),计算耐药指数RI;观察益气化瘀解毒方对耐药细胞的增殖影响;采用荧光定量PCR检测药物干预前后2种细胞中MRP、GST-π和Topo Ⅱ基因表达水平。结果亲本细胞和耐药细胞Sorafenib的IC50值分别为(7.993±0.522)μmol/L和(19.651±1.216)μmol/L,RI约为2.5。益气化瘀解毒方可抑制耐药细胞的增殖活性。2种细胞的MRP、GST-π、Topo Ⅱ表达量无明显差异(P>0.05)。Sorafenib组可促进耐药细胞MRP 、GST-π基因的过表达(P<0.05),益气化瘀解毒方组可抑制GST-π基因的过表达(P<0.01),且联合Sorafenib可显著提高Topo Ⅱ基因的表达量(P<0.01)。结论 QGY7702/Sora细胞MRP、GST-π和Topo Ⅱ的表达水平与亲本细胞无显著差异。耐药细胞对Sorafenib敏感性降低与MRP、GST-π过表达相关,而益气化瘀解毒方拮抗Sorafenib耐药与抑制GST-π过表达相关。 相似文献
14.
Subdental synchondrosis and anatomy of the axis in aging: a histomorphometric study on 30 autopsy cases 总被引:4,自引:4,他引:0
Matthias Gebauer Christian Lohse Florian Barvencik Pia Pogoda Johannes M. Rueger Klaus Püschel Michael Amling 《European spine journal》2006,15(3):292-298
During skeletal development the two ossification centers of the odontoid process are separated from the corpus of the axis by a subdental synchondrosis. This synchondrosis is thought to close and disappear spontaneously in adolescence although this has never been studied in detail. The basis of the dens is of clinical relevance as type II dens fractures are located here. To characterize the morphological architecture of the axis with particular attention to the subdental synchondrosis, the complete axis was harvested from thirty age-matched and gender-matched patients of the three different age groups at autopsy. The subdental synchondrosis and the bone structure of the dens, the basis of the dens and the body of C2 were analyzed by radiography, histology and quantitative histomorphometry. At the macroscopic level the persistency of the subdental synchondrosis in the adult cervical spine was detected in 87% (26 of 30) of the specimens. Histomorphometry revealed a residual disc blastema with an average size of 25.8% of the sagittal depth of the basis of the dens at this level. Bony integration of the synchondrosis was poor throughout all ages. Histologically a cartilaginous matrix composition of the subdental synchondrosis persisted throughout all groups. The trabecular microarchitecture demonstrated a significant reduction of bone volume and trabecular number as well as an increased trabecular separation within the basis of the dens as compared to the corpus or the dens of C2. This histomorphometric data regarding a poor integration of the synchondrosis into the trabecular network and the reduced bone mass within the basis of the dens might offer a previously underestimated explanation for the occurrence of type II dens fractures and their association with pseudoarthrosis, respectively.Matthias Gebauer and Christian Lohse contributed equally to this study and therefore share first authorship. 相似文献
15.
Summary— KR31080 (2-butyl-5-methyl-6-(1-oxopyridin-2-yl)-3-[[2'-(1H-tetrazol-5-yl) biphenyl-4-yl]methyl]-3H-imidazo[4,5-b] pyridine) is a potent inhibitor of angiotensin type 1 (AT1 ) receptors in rabbit aorta and human recombinant AT1 receptors. In the isolated rabbit thoracic aorta, KR31080 caused a nonparallel shift to the right of the concentration-response curves to angiotensin II (All) with decreased maximal response (pD'2 = 10.1 ± 0.1), but had no effect on the contractile response induced by norepinephrine. KR31080 inhibited specific [125 I]AII binding to rabbit aortic membranes (AT, receptors) and [125 I][Sar1 , Ile8 ]AII binding to human recombinant AT1 receptors in a concentration-dependent manner with IC50 values of 0.84 ± 0.08 nM and 1.92 ± 0.15 nM, respectively, but did not inhibit specific [125 I)AII binding to bovine cerebellum membranes (ÀT2 receptors). In the Scatchard analysis, KR31080 interacted with rabbit aortic AT1 receptors in a competitive manner, similar to losartan. These results demonstrate that KR31080 is a potent and AT1 selective angiotensin receptor antagonist which exerts a competitive antagonism in the [125 I]AII binding assay and insurmountable AT1 receptor antagonism in the functional study. 相似文献
16.
17.
18.
H. S. Pollinger M. D. Stegall J. M. Gloor S. B. Moore S. R. Degoey N. A. Ploeger W. D. Park H. S. Pollinger M. D. Stegall J. M. Gloor S. B. Moore S. R. Degoey N. A. Ploeger W. D. Park 《American journal of transplantation》2007,7(4):857-863
The immunologic risk associated with donor-specific antibodies (DSA) against Class II human leukocyte antigens (HLA) in kidney transplant (KTx) recipients is unclear. The aim of this study was to determine the outcome of KTx when DSA was detected only against HLA Class II. To isolate the impact of anti-Class II DSA, we retrospectively analyzed 12 KTx recipients who at baseline had a positive B-cell flow cytometric crossmatch (FXM) and a negative T-cell FXM. Using alloantibody specification analysis, 58.3% (7/12) had DSA against donor Class II and 41.7% had no demonstrable DSA. Biopsy-proven AMR occurred in 57% (4/7) in the Class II(+) group and 0% in the Class II(-) group (p > 0.05). Peritubular capillaries stained positive for C4d in 86% (6/7) of the Class II(+) patients and in 40% (2/5) of the Class II(-) patients (p > 0.05). One patient in the Class II(+) group lost their graft at 3 months to accelerated transplant glomerulopathy, while all other grafts were functioning 3-37 months posttransplant despite the persistence of anti-Class II DSA. We conclude that KTx recipients with clearly defined anti-Class II DSA are at risk for humoral rejection suggesting that desensitization and/or close posttransplant monitoring may be needed to prevent AMR. 相似文献
19.
Phase II clinical trials are performed to investigate whether a novel treatment shows sufficient promise of efficacy to justify its evaluation in a subsequent definitive phase III trial, and they are often also used to select the dose to take forward. In this paper we discuss different design proposals for a phase II trial in which three active treatment doses and a placebo control are to be compared in terms of a single‐ordered categorical endpoint. The sample size requirements for one‐stage and two‐stage designs are derived, based on an approach similar to that of Dunnett. Detailed computations are prepared for an illustrative example concerning a study in stroke. Allowance for early stopping for futility is made. Simulations are used to verify that the specified type I error and power requirements are valid, despite certain approximations used in the derivation of sample size. The advantages and disadvantages of the different designs are discussed, and the scope for extending the approach to different forms of endpoint is considered. Copyright © 2008 John Wiley & Sons, Ltd. 相似文献
20.
日本急救医疗体系比较发达,一般把急救患者分检为I级、II级和III级,再送到相应的医疗机构进行救治。急救医疗从业人员都是专业的人员,能够及时有效地对急救患者进行诊治。现在日本正在进行急救医疗体系的改革,成立了相关委员会并形成一些基础改革,主要是增加急救医疗的投入及专业急救医生的提高。这些对我国急救医疗体系现存的一些问题有一定借鉴意义。 相似文献